{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:05:00Z","timestamp":1783400700736,"version":"3.54.6"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Resolve Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and RNA debris persist in viral reservoirs for weeks to months following infection, potentially triggering interferon production and chronic inflammation. RSLV-132 is a biologic drug composed of catalytically active human RNase1 fused to human IgG1 Fc and is designed to remain in circulation and digest extracellular RNA. We hypothesized that removal of SARS-CoV-2 viral RNA from latent reservoirs may improve inflammation, neuroinflammation, and fatigue associated with post-acute sequelae of SARS-CoV-2 infection (PASC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a phase 2, double-blind, placebo-controlled randomized clinical trial in participants with a 24-week history of PASC and severe fatigue. The primary endpoint of the trial assessed the impact of 6 intravenous doses of RSLV-132 on the mean change from baseline at day 71 in the Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a (PROMIS Fatigue SF 7a).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A statistically significant difference on day 71 was not observed with respect to the primary or secondary endpoints. This was likely due to a placebo response that increased during the trial. Statistically significant improvement in fatigue as measured by the PROMIS Fatigue SF 7a, Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT-Fatigue), and Physicians Global Assessment (PGA) instruments were observed earlier in the trial, with women demonstrating greater responses to RSLV-132 than men.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While fatigue was not statistically significantly improved at Day 71, earlier timepoints revealed statistically significant improvement in fatigue and physician global assessment. The data suggest eliminating latent viral RNA by increasing serum RNase activity may improve fatigue in PASC patients. Women may respond better to this approach than men. Future studies will aim to confirm these findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae205","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T18:20:56Z","timestamp":1715365256000},"page":"635-642","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection: A Randomized Phase 2 Trial of RSLV-132"],"prefix":"10.1093","volume":"79","author":[{"given":"James S","family":"Andrews","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University of Alabama , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim B","family":"Boonyaratanakornkit","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]},{"name":"Department of Infectious Disease, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Krusinska","sequence":"additional","affiliation":[{"name":"Resolve Therapeutics, LLC , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Allen","sequence":"additional","affiliation":[{"name":"Resolve Therapeutics, LLC , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-9612","authenticated-orcid":false,"given":"James A","family":"Posada","sequence":"additional","affiliation":[{"name":"Resolve Therapeutics, LLC , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2024092615365056600_ciae205-B1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2023.8823","article-title":"Development of a definition of postacute sequelae of SARS-CoV-2 infection","volume":"329","author":"Thaweethai","year":"2023","journal-title":"JAMA"},{"key":"2024092615365056600_ciae205-B2","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1038\/s41467-022-33573-6","article-title":"Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparisons in a matched cohort","volume":"13","author":"Horberg","year":"2022","journal-title":"Nat Commun"},{"key":"2024092615365056600_ciae205-B3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","article-title":"Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations","volume":"11","author":"Parotto","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024092615365056600_ciae205-B4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(23)00238-2","article-title":"Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness","volume":"11","author":"Pandharipande","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024092615365056600_ciae205-B5","doi-asserted-by":"crossref","first-page":"1187163","DOI":"10.3389\/fmed.2023.1187163","article-title":"ME\/CFS and long COVID share similar symptoms and biological abnormalities: road map to the literature","volume":"10","author":"Komaroff","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2024092615365056600_ciae205-B6","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41590-023-01601-2","article-title":"SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)","volume":"24","author":"Proal","year":"2023","journal-title":"Nat Immunol"},{"key":"2024092615365056600_ciae205-B7","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciac722","article-title":"Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae","volume":"76","author":"Swank","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024092615365056600_ciae205-B8","first-page":"276","article-title":"Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19","volume":"70","author":"Zuo","year":"2021","journal-title":"Gut"},{"key":"2024092615365056600_ciae205-B9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.medj.2022.04.001","article-title":"Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection","volume":"3","author":"Natarajan","year":"2022","journal-title":"Med"},{"key":"2024092615365056600_ciae205-B10","doi-asserted-by":"crossref","first-page":"e28568","DOI":"10.1002\/jmv.28568","article-title":"Persistent circulation of soluble and extracellular vesicle-linked spike protein in individuals with postacute sequelae of COVID-19","volume":"95","author":"Craddock","year":"2023","journal-title":"J Med Virol"},{"key":"2024092615365056600_ciae205-B11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"2024092615365056600_ciae205-B12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"2024092615365056600_ciae205-B13","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.4049\/jimmunol.175.5.2851","article-title":"Shared and unique functions of the DexD\/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity","volume":"175","author":"Yoneyama","year":"2005","journal-title":"J Immunol"},{"key":"2024092615365056600_ciae205-B14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"key":"2024092615365056600_ciae205-B15","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1084\/jem.20122798","article-title":"Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells","volume":"210","author":"Giltiay","year":"2013","journal-title":"J Exp Med"},{"key":"2024092615365056600_ciae205-B16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nsmb.2943","article-title":"Toll-like receptor 8 senses degradation products of single-stranded RNA","volume":"22","author":"Tanji","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"2024092615365056600_ciae205-B17","doi-asserted-by":"crossref","first-page":"9970","DOI":"10.1073\/pnas.0603912103","article-title":"Tlr7 translocation accelerates systemic autoimmunity in murine lupus","volume":"103","author":"Subramanian","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024092615365056600_ciae205-B18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"2024092615365056600_ciae205-B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"2024092615365056600_ciae205-B20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.1124978","article-title":"Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication","volume":"312","author":"Pisitkun","year":"2006","journal-title":"Science"},{"key":"2024092615365056600_ciae205-B21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","article-title":"Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection","volume":"23","author":"Phetsouphanh","year":"2022","journal-title":"Nat Immunol"},{"key":"2024092615365056600_ciae205-B22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/jcm11020413","article-title":"Female sex is a risk factor associated with long-term post-COVID related-symptoms but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study","volume":"11","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2022","journal-title":"J Clin Med"},{"key":"2024092615365056600_ciae205-B23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00281-018-0712-y","article-title":"Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation","volume":"41","author":"Souyris","year":"2019","journal-title":"Semin Immunopathol"},{"key":"2024092615365056600_ciae205-B24","doi-asserted-by":"crossref","first-page":"eaap8855","DOI":"10.1126\/sciimmunol.aap8855","article-title":"TLR7 escapes X chromosome inactivation in immune cells","volume":"3","author":"Souyris","year":"2018","journal-title":"Sci Immunol"},{"key":"2024092615365056600_ciae205-B25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cell.2023.11.033","article-title":"XIST directly regulates X-linked and autosomal genes in na\u00efve human pluripotent cells","volume":"187","author":"Dror","year":"2024","journal-title":"Cell"},{"key":"2024092615365056600_ciae205-B26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2023.12.037","article-title":"Xist ribonucleoproteins promote female sex-biased autoimmunity","volume":"187","author":"Dou","year":"2024","journal-title":"Cell"},{"key":"2024092615365056600_ciae205-B27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024092615365056600_ciae205-B28","doi-asserted-by":"crossref","first-page":"e001113","DOI":"10.1136\/lupus-2023-001113","article-title":"Evaluation of RNase therapy in systemic lupus erythematosus: a randomized phase 2a clinical trial of RSLV-132","volume":"11","author":"Burge","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2024092615365056600_ciae205-B29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-024-45107-3","article-title":"Deep phenotyping of post-infectious myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"15","author":"Walitt","year":"2024","journal-title":"Nat Commun"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae205\/57505779\/ciae205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/3\/635\/59357025\/ciae205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/3\/635\/59357025\/ciae205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:03:12Z","timestamp":1727366592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/3\/635\/7668392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae205","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,15]]},"published":{"date-parts":[[2024,5,10]]}}}